Pulmatrix, Inc

KalVista Pharmaceuticals, Inc is a biopharmaceutical company based in Cambridge, MA that is dedicated to developing a new generation of small molecule protease inhibitors for the treatment of Hereditary Angioedema (HAE) and Diabetic Macular Edema (DME). Their investigational product candidate, Sebetralstat, is currently in clinical development as an oral on-demand therapy for HAE attacks, showing promising results in reducing the use of rescue treatment, shortening time to symptom relief, and providing sustained cumulative symptom relief. With a focus on innovation and improving patient outcomes, KalVista Pharmaceuticals aims to address the unmet medical needs of individuals suffering from HAE and DME through their pipeline of novel therapies. Their commitment to advancing scientific research and delivering effective treatments is evident in their positive Phase 2 data and the publication of their first oral Factor XIIa data, positioning them as a leading player in the field of protease inhibitors.Generated from the website

Blue Oak Pharmaceuticals Inc is a pioneering biopharmaceutical company based in Concord, MA, dedicated to revolutionizing the treatment of brain disorders. With a focus on developing first-in-class and best-in-class drugs, their breakthrough approach challenges the traditional target-based methods used by the industry, offering new hope to millions of patients and their families who suffer from mental illness. By utilizing an unbiased approach to systems neuroscience and leveraging their privileged chemistry platform, Blue Oak is able to examine the entire brain circuitry and identify drug-like compounds with high efficiency. Their innovative use of predictive AI design, in collaboration with partners Exscientia and PsychoGenics, optimizes small molecules to normalize the behavioral symptoms of brain disorders. With a robust pipeline of clinical programs targeting bipolar depression, treatment-resistant depression, schizophrenia, and geriatric psychosis, Blue Oak is at the forefront of transforming the CNS drug discovery paradigm.Generated from the website

Syntonix Pharmaceuticals is engaged in the discovery and development of novel, long-acting, proprietary therapeutic products that utilize the company s proprietary Fc-fusion proteins and other engineered ligands that bind to specific Fc receptors. These technologies, including the Transceptor drug-delivery platform, are designed to use the body s natural protection of antibodies against premature destruction and for the transport of antibodies across cell barriers. The company focuses on using these technologies to create next-generation treatments for chronic diseases such as hemophilia, anemia and autoimmune disorders. It develops selected products for specialty indications and evaluates and commercializes other products through partnerships. The company occupies a 25,000-square-foot laboratory facility that includes a clinical manufacturing suite. Syntonix Pharmaceuticals is headquartered in Waltham, Mass.